Table 2.
Clinical parameters of patients with different therapeutic responses.
|
ΔCRT ≤ −50 n = 12 (41.38%) |
ΔCRT > −50 n = 17 (58.62%) |
p |
ΔBCVA ≥ 15 n = 8 (27.59%) |
ΔBCVA< 15 n = 21 (72.41%) |
p | |
|---|---|---|---|---|---|---|
| Initial CRT 2 | 477.17 ± 106.90 | 319.00 ± 63.61 | <0.0001* | 420.38 ± 134.10 | 370.76 ± 106.37 | 0.305 |
| Initial HbA1c | 6.65 ± 0.59 | 7.99 ± 1.61 | 0.018* | 7.12 ± 1.41 | 7.60 ± 1.50 | 0.487 |
| Age | 61.17 ± 10.25 | 61.94 ± 7.82 | 0.819 | 57.25 ± 6.09 | 63.29 ± 9.13 | 0.097 |
| Gender | ||||||
| Female | 7 (58.33%) | 6 (35.29%) | 0.274 | 6 (75.00%) | 7 (33.33%) | 0.092 |
| Male | 5(41.67%) | 11 (64.71%) | 2 (25.00%) | 14 (66.67%) | ||
| Initial BCVA (Letters) | 37.42 ± 27.27 | 50.24 ± 31.89 | 0.269 | 18.63 ± 40.19 | 54.95 ± 18.24 | 0.002* |
| Initial IOP | 14.67 ± 2.93 | 15.12 ± 3.33 | 0.709 | 14.13 ± 3.00 | 15.24 ± 3.19 | 0.402 |
| Anti-VEGF injection times | 9.00 ± 4.43 | 7.53 ± 4.32 | 0.379 | 9.88 ± 3.80 | 7.48 ± 4.45 | 0.189 |
| Lens status | ||||||
| Phakic | 9 (75.00%) | 11 (64.71%) | 0.694 | 7 (87.50%) | 13 (61.90%) | |
| Pseudophakic | 3 (25.00%) | 6 (35.29%) | 1 (12.50%) | 8 (38.10%) | ||
*
p < 0.05; BCVA, best-corrected visual acuity; CRT, central retina thickness; HbA1c, glycated hemoglobin; IOP, intraocular pressure; VEGF, vascular endothelial growth factor.